A Phase 1 interventional study of Xiidra and Lifitegrast in Dry Eye Syndromes, sponsored by Qilu Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-27.
Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing lifitegrast in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. lifitegrast · Dry Eye Syndromes.
Among the 22 studies testing lifitegrast in Dry Eye Syndromes, this one is the 16th largest by enrollment, is one of 2 that started in 2022, is the only one in phase 1, and was the 18th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →2 of the 22 studies testing lifitegrast in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:
Toyos Clinic · Sites in United States
Ages 18+
Pittsburgh Research Institute · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
lifitegrast: first FDA approval 2016 (XIIDRA). What it is approved for, and how studies give it, is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 38 across the 22 interventional studies. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 22 have an industry lead sponsor. The 10 most frequent:
Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.
Qilu Pharmaceutical Co., Ltd. has 1 study filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing lifitegrast in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a single-center, randomized, double-blind, single-dose, two-period crossover Phase I clinical trial designed to:
A total of 24 healthy subjects will be randomized into two treatment sequences (Group A: T/R; Group B: R/T). The study duration per subject will be approximately 36 days, including:
On Day 1 of Cycle 1, one study eye will be selected and designated for all subsequent tear PK sampling. Treatment assignments:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females: non-pregnant, non-lactating; premenopausal use approved methods, no egg donation.
Males with fertile partners: vasectomy (≥30 days, no viable sperm) or approved contraception, no sperm donation.
Exclusion Criteria:
Vital signs: ear temp >37.7℃ or \<35.4℃; pulse >100 or \<60 bpm; systolic BP ≥150 or \<90 mmHg; diastolic BP ≥90 or \<50 mmHg.
: ≥450 ms (male), ≥460 ms (female). Lab tests: abnormal blood/urine, coagulation, infectious markers, drug/alcohol screenings.
Abnormal abdominal ultrasound or eye exams.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Xiidra
Drug: Lifitegrast
Administered on Day 1 to subjects in Group B, and on Day 8 to subjects in Group A as part of a crossover study design.
Administered on Day 1 to subjects in Group A, and on Day 8 to subjects in Group B as part of a crossover study design.
Peak Plasma Concentration (Cmax)
Evaluated in plasma and tears.
Time frame: Day 1 & Day 8: Pre-dose, 10, 20, 30, 45 minutes, and 1 hour post-administration.
Area Under the Plasma Concentration-Time Curve (AUC0-∞)
Evaluated in plasma and tears.
Time frame: Day 1 & Day 8: Pre-dose, 10, 20, 30, 45 minutes, and 1 hour post-administration.
Area Under the Plasma Concentration-Time Curve (AUC0-t)
Evaluated in plasma and tears.
Time frame: Day 1 & Day 8: Pre-dose, 10, 20, 30, 45 minutes, and 1 hour post-administration.
Time to Peak Plasma Concentration (Tmax)
Assessment: Evaluated in plasma and tears.
Time frame: Day 1 & Day 8: Pre-dose, 10, 20, 30, 45 minutes, and 1 hour post-administration.
5. Terminal Phase Half-Life (T1/2)
Evaluated in plasma and tears
Time frame: Day 1 & Day 8: Pre-dose, 10, 20, 30, 45 minutes, and 1 hour post-administration.
Elimination Rate Constant (λz)
Evaluated in plasma and tears.
Time frame: Day 1 & Day 8: Pre-dose, 10, 20, 30, 45 minutes, and 1 hour post-administration.
Percentage Extrapolated AUC (AUC_%Extrap)
Evaluated in plasma and tears.
Time frame: Day 1 & Day 8: Pre-dose, 10, 20, 30, 45 minutes, and 1 hour post-administration
Ran from Dec 2022 to primary completion in Dec 2022, 0 months.
Of 34 phase 1 interventional studies under Dry Eye Syndromes, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 0 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lifitegrast
Qilu Pharmaceutical Co., Ltd. →